Onartuzumab (MetMab)

DRUG2 trials

Sponsors

Genentech, Inc., Hoffmann-La Roche

Conditions

Gastric CancerNon-Squamous Non-Small Cell Lung Cancer

Phase 2

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer

CompletedNCT01590719

Hoffmann-La RocheGastric Cancer

Start: 2012-07-31End: 2014-10-31Updated: 2016-08-09

Phase 3

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

CompletedNCT01456325

Genentech, Inc.Non-Squamous Non-Small Cell Lung Cancer

Start: 2012-01-31End: 2016-01-31Updated: 2016-11-02

Related Papers

A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib.

2024-07-311 citations

Dissecting gastric cancer biology and how and when to use immunotherapy

Annals of Oncology2018-10-01

Abstract 5571: Changes in plasma genomic abnormalities at chromosome 8 and 20 predict treatment response and monitor disease progression in advanced gastric cancer

Cancer Research2018-07-01

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.

2016-07-0889 citations

False-negative rate for HER2 testing in 738 gastric and gastroesophageal junction cancers (GEC) from two global randomized clinical trials.

Journal of Clinical Oncology2015-01-2015 citations

Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial.

Journal of Clinical Oncology2014-05-20146 citations